The Institute for Clinical and Economic Review (ICER) today released a Preliminary New Evidence Update for alirocumab (Praluent, Regeneron/Sanofi), based on results from the ODYSSEY outcomes trial presented at this weekend’s American College of Cardiology’s 2018 Scientific Session.
Under ICER’s established protocols for accepting in-confidence data, an agreement with Regeneron and Sanofi allowed ICER to evaluate the new evidence and, working with a team of academic faculty from the University of California, San Francisco, to update its cost-effectiveness analyses and associated value-based price benchmarks for this drug.
ICER’s value-based price benchmarks suggest a price range that aligns fairly with the added benefits of new treatment options for patients and the health care system.
“These new data demonstrate that alirocumab not only lowers levels of bad cholesterol but can also reduce deaths among a patient population with a recent history of an acute coronary event,” said ICER President Steven Pearson.
To read more, click here.